You are here: Industry Insights > Senhwa

News List

Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer prnasia
January 21, 2022
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) ...
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference prnewswire
September 28, 2021
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced the acceptance...
Senhwa Announces IND Submission to India's CDSCO of a Phase II Clinical Study for Silmitasertib as a Potential COVID-19 Treatment prnasia
June 23, 2021
Senhwa today announced that it has submitted an Investigational New Drug (IND) application to India's Central Drugs Standard Control Organization (CDSCO) to evaluate its investigational drug, Silmitasertib, for the treatment of COVID-19.
Senhwa Announces First Patient Enrolled in Silmitasertib Trial for Severe COVID-19 americanpharmaceuticalreview
January 26, 2021
Senhwa Biosciences announced that the first patient has enrolled into an investigator-initiated trial (IIT) of its investigational drug, Silmitasertib, as a treatment for hospitalized COVID-19 patients at Banner Health-University Medical Center in ...
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19 prnasia
January 22, 2021
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investigator-initiated ...
Senhwa Biosciences Presents Positive Cholangiocarcinoma Data prnasia
January 18, 2021
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announces that promising clinical data from their global phase 1b/2 trial, evaluating ...
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations prnasia
November 26, 2020
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced that it has submitted multiple Investigational New Drug (IND) applications to ...